COMPARISON OF SYSTEMIC INFLAMMATION-RELATED HEMATOLOGICAL PARAMETERS IN ACUTE AND CHRONIC LOW BACK PAIN

NCT04897620 | Unknown

• 1 other identifier: 2021-06-10
• Study Type: observational
• Target: 450
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to compare the neutrophils to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), eosinophils to lymphocytes ratio (ELR), red blood cell distribution width (RDW), mean platelet volume (MPV), systemic immune inflammation index (SII), erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) which are the hematological parameters associated with systemic inflammation in acute and subacute/chronic low back pain. Secondary purpose; evaluation of the prognostic roles of hematological parameters associated with systemic inflammation in low back pain in predicting chronicity.This study is a retrospective case-control study. The data of patients who applied to the emergency department with the complaint of acute (less than 4 weeks) low back pain or to the Physical Medicine and Rehabilitation outpatient clinic with the complaint of subacute (lasting 4-12 weeks) or chronic (longer than 12 weeks) non-specific low back pain in the last 3 years will be scanned. The data of patients who applied with complaints other than medical conditions known to be associated with painful conditions and/or inflammatory response will be screened as a control group. The data of patients between the ages of 18-65 will be included in the study. In conclusion, the data of 150 patients who presented with acute non-specific low back pain, 150 patients who presented with subacute/chronic non-specific low back pain and 150 participants as the control group will be included in the study for use in analysis. Participants' age, gender, duration of low back pain (days), if evaluated, conditions associated with low back pain in cases with subacute/chronic pain, ESR, CRP, RDW, MPV, neutrophil count, lymphocyte count, eosinophil count and platelet count in blood tests at admission examinations will be recorded. NLR will be calculated by dividing the number of neutrophils by the number of lymphocytes, PLR by dividing the number of platelets by the number of lymphocytes, ELR by dividing the number of eosinophils by the number of lymphocytes, and SII by the formula "platelet numberxneutrophil number/lymphocyte number".

Conditions

Pain, Chronic

Outcome Measures

Primary Outcomes (8)

• Erythrocyte sedimentation rate

  The erythrocyte sedimentation rate value in blood tests at admission examinations.

  1 month

• C reactive protein

  The C reactive protein value in blood tests at admission examinations.

  1 month

• Red blood cell distribution width

  The red blood cell distribution width value in blood tests at admission examinations.

  1 month

• Mean platelet volume

  The mean platelet volume value in blood tests at admission examinations.

  1 month

• Neutrophils to lymphocytes ratio (NLR)

  NLR is calculated by dividing the number of neutrophils by the number of lymphocytes.

  1 month

• Platelets to lymphocytes ratio (PLR)

  PLR is calculated by dividing the number of platelets by the number of lymphocytes.

  1 month

• Eosinophils to lymphocytes ratio (ELR)

  ELR is calculated by dividing the number of eosinophils by the number of lymphocytes.

  1 month

• Systemic immune inflammation index (SII)

  SII is calculated by the formula "platelet numberxneutrophil number/lymphocyte number.

  1 month

Interventions

Scanning the blood test results OTHER

Participants' age, gender, duration of low back pain (days), if evaluated, conditions associated with low back pain in cases with subacute/chronic pain, ESR, CRP, RDW, MPV, neutrophil count, lymphocyte count, eosinophil count and platelet count in blood tests at admission examinations were recorded. NLR was calculated by dividing the number of neutrophils by the number of lymphocytes, PLR by dividing the number of platelets by the number of lymphocytes, ELR by dividing the number of eosinophils by the number of lymphocytes, and SII by the formula "platelet numberxneutrophil number/lymphocyte number"

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The data of patients between the ages of 18-65 who applied to the emergency department with the complaint of acute (less than 4 weeks) low back pain or to the Physical Medicine and Rehabilitation outpatient clinic with the complaint of subacute (lasting 4-12 weeks) or chronic (longer than 12 weeks) non-specific low back pain in the last 3 years will be scanned. The data of patients who applied with complaints other than medical conditions known to be associated with painful conditions and/or inflammatory response will be screened as a control group.

You may qualify if:

• The data of patients who applied to the emergency department with the complaint of acute (less than 4 weeks) low back pain or to the Physical Medicine and Rehabilitation outpatient clinic with the complaint of subacute (lasting 4-12 weeks) or chronic (longer than 12 weeks) non-specific low back pain in the last 3 years.
• The data of patients between the ages of 18-65.

You may not qualify if:

• Patients who have systemic diseases or internal organ pathologies that may cause low back pain, acute/chronic infection, malignancy, rheumatic disease or systemic diseases that may change the hematological inflammation parameters, which are evaluation parameters,
• Patients who have severe neurological involvement findings in imaging examinations or clinical examination,
• Patients who have a history of surgical procedures for the lumbar region in the last 6 months
• Patients those missing one or more of the parameters planned to be evaluated within the scope of the screened data.

Sponsors & Collaborators

• Ufuk University: lead

Study Sites (1)

Ufuk University

Ankara, Çankaya, 06520, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Chronic Pain

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Elzem Bolkan Günaydın

CONTACT

05309787303; elzembolkan@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer Doctor

Study Record Dates

• First Submitted: May 18, 2021
• First Posted: May 21, 2021
• Study Start: May 5, 2021
• Primary Completion: June 5, 2021
• Study Completion: June 5, 2021
• Last Updated: May 21, 2021

Record last verified: 2021-05

Locations

TU (1)